Intellia Therapeutics, Inc. (NTLA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Intellia Therapeutics, Inc. reported revenue of $67.67M, up 16.9% from the prior year. The company ran a net loss, with a net margin of -609.9%. It held $842.13M in total assets against $170.73M in total liabilities.
Key ratios (FY2025)
-651.7%
Operating margin
-609.9%
Net margin
-61.5%
Return on equity
+16.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.67M | $57.88M | $36.27M | $52.12M | $33.05M | $57.99M | $43.10M | $30.43M | $26.12M | $16.48M |
| Cost of Revenue | — | — | — | — | $0 | $0 | $0 | $0 | — | — |
| Operating Income | -$440.99M | -$534.26M | -$515.29M | -$458.16M | -$267.85M | -$136.58M | -$106.37M | -$90.87M | -$69.56M | -$32.16M |
| Net Income | -$412.69M | -$519.02M | -$481.19M | -$474.19M | -$267.89M | -$134.23M | -$474.19M | -$85.34M | -$67.54M | -$31.63M |
| EPS (Diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | — | — | — | — |
| Total Assets | $842.13M | $1.19B | $1.30B | $1.52B | $1.29B | $676.32M | $334.28M | $347.31M | $376.24M | $298.97M |
| Total Liabilities | $170.73M | $319.06M | $250.81M | $284.53M | — | — | — | — | — | — |
| Shareholders' Equity | $671.39M | $871.96M | $1.05B | $1.24B | $1.04B | $527.07M | $269.88M | $277.92M | $300.60M | $209.84M |
| Cash & Equivalents | $155.46M | $189.18M | $226.75M | $523.51M | $123.41M | $160.02M | $57.23M | $58.86M | $340.68M | $273.06M |
| Operating Cash Flow | -$394.74M | -$348.88M | -$394.09M | -$333.29M | -$225.03M | -$49.91M | -$103.24M | -$61.26M | -$65.28M | $36.11M |
| Capital Expenditures | $1.13M | $5.78M | $13.98M | $13.56M | $12.76M | $3.58M | $6.79M | $6.36M | $10.09M | $6.17M |
| Shares Outstanding | 116.32M | 102.03M | 93.00M | 87.10M | 74.49M | 66.23M | 50.20M | 45.22M | 42.38M | 36.02M |